PreveCeutical(TM) Medical Inc. Announces Requisitions to Acquire State-of-the-Art Instrumentation Expediting Suite of Research and Developments Programs
Vancouver, British Columbia--(Newsfile Corp. - August 14, 2017) - PreveCeutical™ Medical Inc. (CSE: PREV) (FSE: 18H) (the "Company" or "PreveCeutical") announces the Company has acquired four new key instruments to assist in expediting PreveCeutical's current pipeline of innovative Research and Development Programs (R&D). PreveCeutical anticipates delivery and commissioning of all four systems in the next four to six weeks.
Dual Gene Therapy
This program paves the way for preclinical evaluation of proprietary chemistry toward the gene target implicated in both diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
Sol-gel Delivery Platform
Developing what we believe will be the first FDA approved, CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Sol-Gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery.
Venom Re-engineering (Peptide Research Program)
The Company will screen peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.
Engineering Peptide Therapeutics for Non-Addictive Pain Killers
PreveCeutical and partner UniQuest Pty Ltd have signed a letter of intent proposing to expand the use of their disulfide linker technology to develop non-addictive analgesics for moderate to-severe pain.
1) Shimadzu Nexera-i High Performance Liquid Chromatography Systems
The Nexera-i is an advanced completely integrated UHPLC system designed for innovative, intuitive, and intelligent operation. With its high-speed and high-capacity autosampler it is ideal for busy labs running multiple projects, where processing of large sample numbers are required each day.
2) Shimadzu PPSQ Protein Sequencer
The PPSQ-53A Protein Sequencer uses automated Edman degradation chemistry to deliver conclusive N-terminal sequencing from isolated peptides/proteins. Automated Edman degradation chemistry is a robust solution delivering unambiguous sequence data that is much less complex than that derived from mass spectrometry alone.
3) Biotage Isolera Dalton 2000 Flash Chromatography system
This second-generation system is the most advanced mass-directed flash purification system in the World. PreveCeutical have the pleasure in announcing it will take ownership of the very first unit supplied globally, which will let us perform purification and analysis simultaneously, giving unprecedented power and speed in isolating (un)known compounds.
Figure 1: Dalton 2000
Cannot view this image the Dalton 2000? Please visit [http://orders.newsfilecorp.com/files/5434/28438_a1502653956405_52.jpg] to view this image
4) Biotage Initiator + Alstra automated peptide synthesizer
A fully automated microwave peptide synthesizer with functionality such as branching, pre-activation, and UV monitoring capability; this instrument represents best-in-class modality for both small and large-scale synthesis of peptides and peptidomimetics. The Biotage Alstra system gives unrivalled flexibility and reliability in generating purer peptides in higher purity and yields.
Cannot view this image the Biotage Initiator Alstra? Please visit [http://orders.newsfilecorp.com/files/5434/28438_a1502653956484_64.jpg] to view this imageAboutPreveCeutical Medical Inc.
PreveCeutical Medical Inc. (CSE: PREV) (FSE: 18H) is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
The Company currently has one product available for sale, the CELLB9® Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
On Behalf of the Board of Directors
"Stephen Van Deventer"
Chairman & CEO
For further information, please contact:
Director of Corporate Communications & Investor Relations
Forward Looking Statements:
This news release includes certain statements that constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, statements as to the proposed first phase of the Company's venom re-engineering project, business plans of the Company regarding the foregoing, the timing of future activities and the prospects of their success for the Company, and the Company's ability and success in executing its proposed business plans, including a successful IND application. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, complete the proposed research project as planned or the inability of the Company to obtain any required governmental approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, or financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company, including the completion of the proposed research programs. There is no guarantee that the research programs will be successful or that their results can be commercialised by the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.
Source: Newsfile Corp.